PainChek General Discussion, page-13811

I don't want to be too confident in FDA approval given the situation we've seen across a certain failure earlier this year.

However, it does feel like the management of our company are much more equipped to be submitting our application.

I'm not relying on FDA to hit for us to be racing towards $1, I think we can do that without it... solid international growth, potential renewal of Aus Grant, roll out of the kids app, DTC for home care, Philips and then the plethora of potential opportunities that arise from that partnership. There's even the trials in the NHS hospital system that will finish by October, could be some opportunity there too if we're found to reduce challenging behaviours in ED.

all of that could happen before potential FDA approval, then whoosh. This is a massive buying opportunity IMO, ofcourse DYOR but I think we'll be seeing at least 40c by end of the year, if not more.